Vir Biotechnology (NASDAQ:VIR) perks up 4% premarket on light volume in reaction to its announcement that
it has identified two monoclonal antibodies that bind the coronavirus
causing the current outbreak, COVID-19 (formerly 2019-nCov).
The company says it is assessing neutralization
with a pseudo-virus and is working with international partners to assess
neutralization with the live virus.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.